Google Scholar | Citations: 16429| h-index: 32 | i10-index: 482
The impact of the COVID-19 pandemic on lipid levels
PDF (Portuguese (Brazil))

Keywords

Cholesterol
LDL-Cholesterol
HDL-Cholesterol
Triglycerides
COVID-19

How to Cite

The impact of the COVID-19 pandemic on lipid levels. (2026). Electronic Journal Collection Health, 26(8), e24619. https://doi.org/10.25248/reas.e24619.2026

Copyright © | All rights reserved.

The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.

Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.

Total reproduction
It is expressly prohibited and must be authorized by the journal.

Abstract

Objective: To conduct an epidemiological survey of the lipid profile of patients treated in the years 2019, 2021, and 2023. Methods: This is a retrospective study based on information extracted from blood samples collected in 2019, 2021, and 2023. The data were tabulated in Excel spreadsheets, forming a database. The associated variables were analyzed using ANOVA, Tukey’s multiple comparisons test, and the chi-square test of independence. Results: Lipid profiles of patients treated at the Clinical Laboratory of PUC Goiás were analyzed during the pre-pandemic period, the pandemic peak, and the post-pandemic period, focusing on changes associated with the COVID-19 pandemic. The chi-square test of independence, ANOVA, and Tukey’s test showed p<0.001, reinforcing the change in total cholesterol in the samples analyzed from 2019 to 2023. The data support the idea that there was a real reduction in the number of patients with elevated LDL levels. Conclusion: Despite limitations, the results highlight cardiovascular prevention, health education, therapeutic adherence, and physical activity as measures to mitigate cardiac risk and prevent dyslipidemia and metabolic syndrome in the post-pandemic period.

PDF (Portuguese (Brazil))

References

ABDULAN IM, et al. Evolução dos Fatores de Risco Cardiovascular em Pacientes Pós-COVID. Revista de medicina clínica, 2023; 12(20): e6538.

AKPEK M. Does COVID-19 Cause Hypertension? Angiology, 2022; 73: 682–687.

ARVANITIS M, LOWENSTEIN CJ. Dyslipidemia. Ann Intern Med, 2023; 176(6).

BERNARDES PRAA. Perfil lipídico e declínio cognitivo em indivíduos com Diabetes Mellitus. Tese (Doutorado), 2025: 81.

MANCINI GBJ, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee, Dyslipidemia. Canadian Journal of Diabetes, 2018; 42(Suppl 1): S178–S185.

DISSANAYAKE H. COVID-19 and metabolic syndrome. Best Pract Res Clin Endocrinol Metab, 2023; 37(4): e101753.

FAHED G, et al. Metabolic Syndrome: Updates on Pathophysiology and Management. Int J Mol Sci, 2022; 23(2): e786.

IQBAL J, et al. Metabolic Syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism. Curr Diabetes Rev, 2018; 14(5): 427–433.

LIU Y, et al. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J, 2021; 18(1): 157.

MEHANDRU S, MERAD M. Pathological sequelae of long-haul COVID. Nat Immunol, 2022; 23: 194–202.

NOGUEIRA CAA, et al. COVID-19 and obesity in childhood and adolescence: a clinical review. J Pediatr, 2020; 96(5): 546–558.

NOUR TY, ALTINTAŞ KH. Effect of the COVID-19 pandemic on obesity and its risk factors: A systematic review. BMC Public Health, 2023; 23: e1018.

O’HEARN M, et al. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis. J Am Heart Assoc, 2021; 10: e019259.

ROCCAFORTE V, et al. Altered lipid profile in patients with COVID-19 infection. J Lab Precis Med, 2020; 6: 2.

RACHED, et al. Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025. Arq Bras Cardiol, 2025; 122(9): e20250640.).

STEENBLOCK C, et al. Obesidade e COVID-19: Quais são as Consequências? Horm Metab Res, 2022; 54: 496–502.

WRONA M, et al. Diabetes Mellitus, Hypertension, Dyslipidaemia as Sequelae of COVID-19 Infection—Systematic Review. Int J Environ Res Public Health, 2022; 19(20): e13280.

XU E, et al. Risks and burdens of incident dyslipidaemia in long COVID: A cohort study. Lancet Diabetes Endocrinol, 2023; 11: 120–128.

ZHANG S, et al. Plasma Metabolomic Profiles in Recovered COVID-19 Patients without Previous Underlying Diseases 3 Months after Discharge. J Inflamm Res, 2021; 14: 4485–4501.

ZUIN M, et al. Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis. High Blood Press Cardiovasc Prev, 2023; 30: 227–233.